Welcome to the JOURNAL OF ORAL PATHOLOGY & MEDICINE, a distinguished publication dedicated to advancing knowledge within the realms of oral pathology and medicine. Published by WILEY since 1972, this journal has established itself as a critical resource for researchers and practitioners alike, covering a broad spectrum of topics related to oral health and disease. With an impressive array of rankings, including Q1 status in categories such as Oral Surgery and Periodontics, and a prominent position in Otorhinolaryngology, the journal is recognized for its substantial contributions to these fields. Although currently not open access, it remains pivotal in disseminating vital research findings, fostering collaboration and innovation among healthcare professionals. The interdisciplinary scope of the journal also supports its high impact factor and robust Scopus rankings, including a 92nd percentile in Otorhinolaryngology. By providing a platform for original research and reviews, the JOURNAL OF ORAL PATHOLOGY & MEDICINE plays an essential role in shaping future advancements in oral health sciences.

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, published by Taylor & Francis AS, serves as a pivotal platform for facilitating advanced research and discourse in the fields of Genetics, Molecular Biology, Molecular Medicine, and Pathology. With an impressive Impact Factor and a distinguished status as Q2 in multiple categories, along with a prestigious Q1 ranking in Pathology and Forensic Medicine (2023), this journal continues to attract contributions from leading experts and budding researchers alike. The journal aims to address critical developments in molecular diagnostics, providing insightful reviews that propel the understanding and application of diagnostic techniques in various medical contexts. Accessible to a diverse audience in the academic community, the journal emphasizes the importance of molecular diagnostics in both clinical and laboratory settings, promoting innovative methodologies and comprehensive evaluations of emerging technologies. With ongoing convergence of scientific discovery advancing rapidly from 2001 through 2024, EXPERT REVIEW OF MOLECULAR DIAGNOSTICS remains essential for those committed to furthering the fields of molecular diagnostics and healthcare advancements globally.

Diagnostic Pathology is a prominent open-access journal published by BMC, dedicated to advancing the field of pathology by providing a platform for high-quality research findings since its inception in 2006. Based in the United Kingdom, the journal covers a broad spectrum of topics within the realms of histology, pathology, and forensic medicine, facilitating discussions that are crucial for both clinical and laboratory settings. With an impressive impact factor that places it in the Q2 category across multiple categories including Histology and Miscellaneous Medicine, it ranks favorably in Scopus with notable positions in the 71st and 55th percentiles for Pathology and Histology respectively. As a valuable resource for researchers, professionals, and students alike, Diagnostic Pathology promotes the dissemination of cutting-edge studies and findings, thereby contributing significantly to the evolving landscape of medical science. The journal’s commitment to open access enhances its accessibility, ensuring that valuable research is freely available to a global audience.

Cancer Biomarkers is a leading journal in the field of cancer research, aimed at the exploration and identification of novel biomarkers for cancer detection, prognosis, and therapy. Published by IOS PRESS in the Netherlands, this journal serves as a pivotal resource for those engaged in oncology, genetics, and molecular biology, facilitating access to cutting-edge research and advancements within these disciplines. In its ongoing mission since 2005, the journal has become an essential reference point, currently occupying a Q3 category in Cancer Research, Genetics, and Oncology, and a Q2 category in miscellaneous Medicine fields. With its commitment to high-quality peer-reviewed articles, Cancer Biomarkers satisfies the intellectual appetite of researchers, clinicians, and students alike, contributing significantly to the ever-evolving landscape of cancer biomarker discovery and application. Though currently not available as Open Access, the journal maintains a robust presence in academic circles, underscored by respectable Scopus rankings across relevant categories.

Laboratory Investigation is a premier academic journal published by Elsevier Science Inc, specializing in the fields of Pathology, Forensic Medicine, Cell Biology, and Molecular Biology. With its ISSN 0023-6837 and E-ISSN 1530-0307, this journal has been a significant contributor to scientific discourse since its inception in 1952, converging into its current form by 2024. It holds an impressive standing in its respective fields, featuring a 2023 Journal Rank of Q2 in both Cell Biology and Molecular Biology, and an elite Q1 ranking in Pathology and Forensic Medicine, reflecting its influence and quality of research, as seen in its Scopus ranks—17th out of 208 in Pathology and Forensic Medicine. Although it does not offer Open Access options, the journal remains a vital resource for researchers, professionals, and students who seek to disseminate and engage with high-caliber research findings. The importance of Laboratory Investigation is underscored by its commitment to advancing the understanding of laboratory and translational medicine, paving the way for innovations that enhance clinical practices.

Precision Clinical Medicine, published by Oxford University Press, is an esteemed open-access journal that has been at the forefront of clinical research since its inception in 2018. With an ISSN of 2096-5303, this journal specializes in the rapidly evolving field of precision medicine, which aims to tailor healthcare to individual patient characteristics, needs, and preferences. As a testament to its influence, Precision Clinical Medicine holds a remarkable rank of #34 out of 636 in the General Medicine category on Scopus, placing it within the 94th percentile of its field and earning a prestigious Q1 rating in 2023. Based in the United Kingdom, the journal not only provides open access content, ensuring that groundbreaking research is widely disseminated, but also serves as a crucial platform for innovations and discussions that shape modern medical practices. Researchers, professionals, and students alike will find valuable insights and influential studies that drive the future of personalized healthcare within its pages.

Welcome to the Journal of Pathology, a premier academic publication specializing in the field of pathology and forensic medicine. Established in 1969 and published by Wiley, this journal has garnered significant recognition within the research community, reflected in its impressive ranking of #6 out of 208 in Scopus, placing it in the 97th percentile. The Journal of Pathology serves as a critical platform for disseminating cutting-edge research findings, innovative methodologies, and topical reviews that advance our understanding of diseases and their underlying mechanisms. With no open access charge, this esteemed journal is committed to maintaining the highest standards of scientific rigor and integrity. As a Q1 journal in its category for 2023, it continues to shape the field of pathology and contribute invaluable insights to researchers, medical professionals, and students alike. We invite you to explore the wealth of knowledge encapsulated in each issue and engage with the vibrant discussions that strive to propel the science of pathology forward.

JOURNAL OF CLINICAL PATHOLOGY, published by BMJ PUBLISHING GROUP, stands at the forefront of advancements in the field of clinical pathology, offering a platform for groundbreaking research and insights from 1948 to the present. With an impressive impact factor and categorized as Q1 in both Medicine (miscellaneous) and Pathology and Forensic Medicine for 2023, the journal holds a distinguished position in the academic community, ranking 22nd out of 208 journals in its category on Scopus and representing the 89th percentile. While the journal does not currently offer open access, it remains a vital resource for researchers, healthcare professionals, and students seeking to stay current with innovative methodologies, clinical techniques, and diagnostic advancements. Located in London, United Kingdom, the journal aims to bridge the gap between laboratory findings and clinical practice, emphasizing the importance of evidence-based pathology in improving patient care and treatment outcomes. Engage with the JOURNAL OF CLINICAL PATHOLOGY to enhance your understanding and contribute to the evolving landscape of clinical pathology research.

Cancer Genetics is an esteemed peer-reviewed journal dedicated to advancing the field of cancer research through the lens of genetics. Published by Elsevier Science Inc and available in both print (ISSN: 2210-7762) and online (E-ISSN: 2210-7770), this journal aims to provide a platform for the dissemination of high-quality studies that unravel the genetic underpinnings of cancer. Since its inception in 2011, Cancer Genetics has become a significant resource for researchers, professionals, and students with a shared interest in understanding the intricate relationship between genetics and oncogenesis. With an impact factor that reflects its influence, the journal has maintained a Q3 ranking in Cancer Research, Genetics, and Molecular Biology as of 2023, indicating its growing importance in these fields. Additionally, the journal offers open access options to ensure that crucial findings are easily accessible to the global research community. By bridging the gap between genetics and cancer studies, Cancer Genetics plays a pivotal role in fostering innovation and collaboration among scientists and clinicians striving to improve cancer diagnosis and treatment.

Biomarker Research is a leading open access journal published by BMC, dedicated to advancing the field of biomarker discovery and clinical application. Since its inception in 2013, this journal has become a crucial resource for researchers and professionals in biochemistry, clinical biochemistry, and molecular medicine, achieving a prestigious Q1 ranking in each category in 2023. With an E-ISSN of 2050-7771, it maintains a strong reputation for disseminating high-quality research and innovative findings that contribute to the understanding of disease mechanisms and the development of novel diagnostics and therapeutics. The journal is accessible to a global audience, ensuring that vital research is freely available to promote collaboration and accelerate scientific progress. Operating out of the United Kingdom, Biomarker Research plays a significant role in addressing some of the most pressing challenges in medical research, making it an essential resource for academics, clinicians, and industry professionals alike.